Krebs Biochemicals & Industries Ltd Share Price

Krebs Biochem
Small Cap | Pharmaceuticals
₹ No value
Last updated: 27-Sep-2025 , 5 min delay

Krebs Biochemicals & Industries Ltd Live Price Chart

Low: ₹0 High: 0
Open Your Trading & Demat Account
+91

Krebs Biochemicals & Industries Ltd Technicals

Current Price
₹ No value
EMASMA
20 Day ₹ 75.903
50 Day ₹ 77.116
100 Day ₹ 79.068
200 Day ₹ 81.029
20 Day ₹ 75.225
50 Day ₹ 76.865
100 Day ₹ 79.281
200 Day ₹ 84.933

Krebs Biochemicals & Industries Ltd Performance

Previous Close ₹
High ₹
Volume 11014
52W Range ₹ 66.12 - ₹ 129.07
Open ₹
Low ₹
Market Cap 152.33 Cr

Krebs Biochemicals & Industries Ltd Fundamentals

ROCE -18.526
P/E Ratio -5.620
P/B Ratio 0.000
Industry P/E 0.000
Debt to Equity 38.991
ROE 18.421
EPS -12.570
Dividend Yield 0.000
Book Value -67.827
Face Value 10.000

Krebs Biochemicals & Industries Ltd Financials

Particulars Y202503 Y202403 Y202303 Y202203 Y202103
Total Revenue 44.0208 50.8728 52.7546 60.8589 54.3217
Total Expenses 70.9448 70.6012 77.4465 105.3857 82.6803
Profit After Tax -26.9393 -19.7284 -24.6919 -44.5268 -28.3586

Krebs Biochemicals & Industries Ltd Shareholding Pattern

Promoter Holdings 72.745 %
FIIs 0.496 %
DIIs 0.000 %
MutualFund 0.000 %
Retail 19.727 %
Others - 7.033 %

About Krebs Biochemicals & Industries Ltd

History of Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Ltd (Formerly Krebs Biochemicals Ltd), promoted by R T Ravi in 1991 is engaged in the manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same. Krebs develops commercially viable biotech processes for application in medicine, agriculture and industry. Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies. KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA. KBL went to public with an IPO in 1994. During 2001-02 ...

Similar Stocks

Company 52 Week Market Price P/E Ratio
Jubilant Pharmova Ltd ₹ 802 - ₹ 1309.9 0.00 472.49
Gujarat Themis Biosyn Ltd ₹ 208 - ₹ 424.9 0.00 97.44
Aarti Drugs Ltd ₹ 312 - ₹ 564.05 0.00 24.14
Hikal Ltd ₹ 245 - ₹ 464.75 0.00 49.86
Krebs Biochemicals & Industries Ltd ₹ 66.12 - ₹ 129.07 0.00 -5.62

FAQs on Krebs Biochemicals & Industries Ltd

1. Can I buy Krebs Biochemicals & Industries Ltd from PL Capital? ›

Yes, you can invest in Krebs Biochemicals & Industries Ltd shares directly through PL Capital. Our platform provides a seamless and secure way to buy, hold, and track Krebs Biochemicals & Industries Ltd stock along with other leading companies listed on the NSE and BSE. Simply open a Demat and trading account with PL Capital, and you’ll be able to trade Krebs Biochemicals & Industries Ltd as well as diversify your portfolio across equities, mutual funds, IPOs, and more.

2. Does Krebs Biochemicals & Industries Ltd pay dividends? ›

Krebs Biochemicals & Industries Ltd does not currently pay dividends. Investors in this case primarily benefit from capital appreciation, where the value of the stock may rise over time depending on business growth and market conditions.

3. What is the current share price of Krebs Biochemicals & Industries Ltd ? ›

As of 26-09-2025 the share price for Krebs Biochemicals & Industries Ltd. is 71.05 on the NSE (Note: Prices are dynamic and update frequently during market hours).

4. What is the 52-week high and low of Krebs Biochemicals & Industries Ltd ? ›

The 52-week high and low of Krebs Biochemicals & Industries Ltd share price is ₹ 66.12 - ₹ 129.07 as of 26-09-2025 .
PL Ringside View

Our fireside chat series where industry experts and top management share valuable insights for our clients

Youtube

Mark Mobius on India’s Growth, Global Markets, and Investment Opportunities

Youtube

₹100 cr net profit in 7-12 months | Anjali Nashier, Revolt Motors

Youtube

India's Path to Energy Security | Dr. Praveer Sinha, MD & CEO, Tata Power

  • PL Capital Logo

  • Regd. Office : 3rd Floor, Sadhana House,
    570, P. B. Marg, Behind Mahindra Tower,
    Worli, Mumbai - 400 018, India

    View on Google Maps

  • Tel. : 02266322222

    Call us

Prabhudas Lilladher Private Limited | CIN: U67190MH1983PTC029670 | Registered Office Address: 3rd Floor, Sadhana House, 570, P.B. Marg, Worli, Mumbai – 400018, Maharashtra, India | SEBI Registration Details: Stock Broking: INZ000196637 [Membership Codes: NSE – 05977; BSE – 564; MCX – 40690] | Depository Participant: IN-DP-439-2019 [DP Codes: CDSL – 12011300; NSDL – IN303868 | Portfolio Management: INP000009001| Research Analyst: INZ000000271 | Investment Advisors: INA000018267 [BSEASL Membership Code: BASL2042] | AMFI ARN: 3276 | Compliance Officer: Mrs. Snehal Kathrani; Tel: 02266322420; email: co@plindia.com | For any Grievance/ Dispute: Stock Broking; email: grievance-br@plindia.com; Tel: 02266322366; Depository Participant; email: grievance-dp@plindia.com; Tel: 02266322452; Portfolio Management; email: grievance-pms@plindia.com; Tel: 02266322350.

To register your grievance on SCORES log onto: https://scores.gov.in/scores/Welcome.html. Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, Email ID

To register your grievance on Smart ODR Portal log onto: Online Dispute Resolution Portal (ODR Portal).

Standard Disclaimers: (a) Investment in securities market are subject to market risks, read all the related documents carefully before investing. (b) Brokerage will not exceed the SEBI prescribed limits. (c) Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

The brand name and Logo ‘PL Capital’ are the registered trademarks of Prabhudas Lilladher Advisory Services Private Limited which is the holding company of Prabhudas Lilladher Group of Companies .

Prabhudas Lilladher Private Limited is not associated with any unregulated platform which claims performance/return for algorithmic strategy for trading. Trading with unregulated platforms for algorithmic strategy shall be at your own risk and Prabhudas Lilladher Private Limited or its affiliates shall not be liable for the same.

Risk Disclosure on Derivatives: (a) 9 out of 10 individual traders in equity futures and options segment, incurred net losses. (b) On an average, loss makers registered net trading loss close to ₹ 50,000 (c) Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs. (d) Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source